Minimum-volume standards could restrict care at many centers with better-than-expected outcomes.
The sNDA is supported by data from the multicenter phase 2 QUADRA trial that evaluated the safety and activity of Zejula in 463 patients.
[Cancer Management and Research] A meta-analysis of randomized controlled trials sought to confirm the effectiveness and safety of olaparib for the treatment of relapsed BRCA-mutated ovarian cancer.
When paired with bevacizumab, neither intraperitoneal delivery of carboplatin nor cisplatin improved outcomes for patients with advanced ovarian carcinoma compared with intravenous delivery.
The Food and Drug Administration (FDA) has recommended that ImmunoGen, Inc. conduct a new phase 3 randomized trial to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) in patients with high folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.